Carboxymethyllysine in Dermal Tissues of Diabetic and Nondiabetic Patients with Chronic Renal Failure: Relevance to Glycoxidation Damage

Carboxymethyllysine (CML) is currently recognized as a major advanced glycation end product and a marker for glycoxidation. Plasma CML levels are increased in patients with chronic renal failure (CRF). However, significance and mechanism of CML accumulation in these patients are poorly understood. The objective of the present study was to analyze CML in soluble and collagen-binding fractions of the dermis to investigate CML deposition and formation and collagen damage related to CML accumulation in patients with CRF. Skin samples (among them autopsy samples) were obtained from 33 subjects: 8 nondiabetic CRF patients, 7 diabetic predialysis patients with CRF (CRF-DM), 7 hemodialysis patients, and 11 control subjects without either CRF or DM. The dermal samples were extracted sequentially by phosphate-buffered normal saline, pepsin, and collagenase. The extracts were referred to as the soluble fraction and the proteinase-extracted fraction (including pepsin-extracted and collagenase-extracted fractions). Our ELISA assay for CML in dermal collagen from predialysis patients with CRF (CRF and CRF-DM groups) demonstrated that the levels of CML in both the soluble fraction (containing soluble CML which was mainly determined by serum clearance) and the structural collagen-binding proteinase-extracted fraction (in which high CML levels could be a strong indication of in situ formation) were increased and could not be completely reduced after hemodialysis in CRF-DM and CRF groups. These results suggest that accumulation of CML may be due to both a low serum clearance and/or increased in situ CML formation in CRF. CML contents in the proteinase extracted fraction inversely correlated with the susceptibility of collagen to extraction by proteinases (n = 33, r = –0.59, p < 0.001). Our results provide the first biochemical evidence that CML level is increased in both the soluble and collagen-binding fractions and that increased CML level resulted in increased fractions of proteinase-resistant collagen in dermal extracts of patients with CRF.

[1]  N Taniguchi,et al.  Glycoxidation in aortic collagen from STZ-induced diabetic rats and its relevance to vascular damage. , 1998, Atherosclerosis.

[2]  V. Monnier,et al.  Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. , 1997, The Journal of clinical investigation.

[3]  E. Diamandis,et al.  The serum concentration of the advanced glycation end-product Nε-(carboxymethyl)lysine is increased in uremia: Technical Note , 1997 .

[4]  P. McNamee,et al.  Susceptibility of VLDL to oxidation in patients on regular haemodialysis. , 1997, Atherosclerosis.

[5]  池田和義.  N[ε]-(Carboxymethyl)lysine Protein Adduct Is a Major Immunological Epitope in Proteins Modified with Advanced Glycation End Products of the Maillard Reaction(カルボキシメチルリジン付加体はメイラード反応後期生成物の主要エピトープある) , 1997 .

[6]  E. Diamandis,et al.  Technical note. The serum concentration of the advanced glycation end-product N epsilon-(carboxymethyl)lysine is increased in uremia. , 1997, Kidney international.

[7]  T. Miyazaki,et al.  Amyloid β2-microglobulin is modified with Nε-(carboxymethyl)lysine in dialysis-related amyloidosis , 1996 .

[8]  J. Baynes,et al.  Role of the Maillard Reaction in Diabetes Mellitus and Diseases of Aging , 1996, Drugs & aging.

[9]  S. Horiuchi,et al.  Advanced Glycation End Products of the Maillard Reaction in Aortic Pepsin-Insoluble and Pepsin-Soluble Collagen From Diabetic Rats , 1996, Diabetes.

[10]  S. Horiuchi.  Advanced Glycation End Products (AGE)-Modified Proteins and Their Potential Relevance to Atherosclerosis. , 1996, Trends in cardiovascular medicine.

[11]  H. Sano,et al.  N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. , 1996, Biochemistry.

[12]  V. Monnier,et al.  Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  T. Miyazaki,et al.  Amyloid beta 2-microglobulin is modified with N epsilon-(carboxymethyl)lysine in dialysis-related amyloidosis. , 1996, Kidney International.

[14]  J. Baynes,et al.  Pathways of formation of glycoxidation products during glycation of collagen. , 1995, Biochemistry.

[15]  J. Baynes,et al.  N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. , 1995, Biochemistry.

[16]  S. Jimi,et al.  Nonenzymatic glycation and extractability of collagen in human atherosclerotic plaques. , 1995, Atherosclerosis.

[17]  M. Robertson,et al.  Oxidation of low density lipoproteins from patients with renal failure or renal transplants. , 1995, Kidney international.

[18]  V. Monnier,et al.  Mechanism of Protein Modification by Glyoxal and Glycolaldehyde, Reactive Intermediates of the Maillard Reaction (*) , 1995, The Journal of Biological Chemistry.

[19]  J. Baynes,et al.  Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. , 1995, Biochemistry.

[20]  M. Smith,et al.  Advanced Maillard reaction end products are associated with Alzheimer disease pathology , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. McNamee,et al.  Oxidative stress in haemodialysis. , 1994, QJM : monthly journal of the Association of Physicians.

[22]  C. W. Scott,et al.  Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Baynes,et al.  Glycation, Glycoxidation, and Cross-Linking of Collagen by Glucose: Kinetics, Mechanisms, and Inhibition of Late Stages of the Maillard Reaction , 1994, Diabetes.

[24]  N. Taniguchi,et al.  beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. , 1993, The Journal of clinical investigation.

[25]  L. L. Moore,et al.  Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. , 1993, The Journal of clinical investigation.

[26]  T. Lyons,et al.  Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. , 1993, The Journal of clinical investigation.

[27]  V. Monnier,et al.  Effects of kidney or kidney-pancreas transplantation on plasma pentosidine. , 1993, Kidney international.

[28]  Paul J Thornalley,et al.  Mechanism of the degradation of non-enzymatically glycated proteins under physiological conditions. Studies with the model fructosamine, N epsilon-(1-deoxy-D-fructos-1-yl)hippuryl-lysine. , 1992, European journal of biochemistry.

[29]  J. Baynes,et al.  Role of Oxygen in Cross-Linking and Chemical Modification of Collagen by Glucose , 1992, Diabetes.

[30]  V. Monnier,et al.  Chromatographic Quantitation of Plasma and Erythrocyte Pentosidine in Diabetic and Uremic Subjects , 1992, Diabetes.

[31]  Y. Morino,et al.  Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. Evidence for the presence of a common structure. , 1991, The Journal of biological chemistry.

[32]  J. Baynes.  Role of Oxidative Stress in Development of Complications in Diabetes , 1991, Diabetes.

[33]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[34]  J. Baynes,et al.  Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. , 1986, The Journal of biological chemistry.

[35]  R. Kohn,et al.  Effects of age and diabetes mellitus on the solubility and nonenzymatic glucosylation of human skin collagen. , 1981, The Journal of clinical investigation.

[36]  H. Stegemann,et al.  Determination of hydroxyproline. , 1967, Clinica chimica acta; international journal of clinical chemistry.